X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19) 19
female (18) 18
oncology (17) 17
middle aged (16) 16
index medicus (13) 13
breast cancer (12) 12
tamoxifen (11) 11
adult (10) 10
article (10) 10
aged (9) 9
breast neoplasms - drug therapy (8) 8
breast neoplasms - prevention & control (8) 8
tamoxifen - therapeutic use (8) 8
postmenopausal women (7) 7
risk factors (7) 7
surgical adjuvant breast (7) 7
cancer (6) 6
clinical trials (6) 6
follow-up studies (6) 6
quality of life (6) 6
risk (6) 6
women (6) 6
antineoplastic agents, hormonal - therapeutic use (5) 5
carcinoma (5) 5
chemotherapy (5) 5
raloxifene (5) 5
tamoxifen - administration & dosage (5) 5
abridged index medicus (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
breast neoplasms - epidemiology (4) 4
chemotherapy, adjuvant (4) 4
double-blind method (4) 4
incidence (4) 4
medicine & public health (4) 4
obesity (4) 4
postmenopause (4) 4
prevention (4) 4
raloxifene hydrochloride - therapeutic use (4) 4
tamoxifen - adverse effects (4) 4
antineoplastic agents, hormonal - administration & dosage (3) 3
antineoplastic agents, hormonal - adverse effects (3) 3
body mass index (3) 3
breast cancer prevention (3) 3
breast neoplasms - diagnosis (3) 3
breast neoplasms - pathology (3) 3
breast neoplasms - radiotherapy (3) 3
cyclophosphamide - administration & dosage (3) 3
doxorubicin - administration & dosage (3) 3
drug therapy (3) 3
medicine, general & internal (3) 3
neoplasm invasiveness (3) 3
prospective studies (3) 3
quality-of-life (3) 3
radiotherapy (3) 3
randomized-trial (3) 3
research (3) 3
skin and connective tissue diseases (3) 3
surveys and questionnaires (3) 3
survival rate (3) 3
therapy (3) 3
womens health (3) 3
adjuvant chemotherapy (2) 2
administration, oral (2) 2
alfacalcidol (2) 2
amenorrhea (2) 2
amenorrhea - chemically induced (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
aromatase inhibitors (2) 2
aromatase inhibitors - administration & dosage (2) 2
aromatase inhibitors - therapeutic use (2) 2
biometry (2) 2
bowel project (2) 2
bowel project p-1 (2) 2
breast cancer risk (2) 2
breast neoplasms - mortality (2) 2
breast neoplasms - surgery (2) 2
calcifediol (2) 2
cancer research (2) 2
cancer surgery (2) 2
carcinoma, ductal, breast - drug therapy (2) 2
carcinoma, ductal, breast - radiotherapy (2) 2
carcinoma, ductal, breast - surgery (2) 2
cataract - epidemiology (2) 2
chemotherapy, adjuvant - adverse effects (2) 2
colon cancer (2) 2
colonic neoplasms - drug therapy (2) 2
endocrine therapy (2) 2
endometrial neoplasms - chemically induced (2) 2
estrogen antagonists - therapeutic use (2) 2
estrogen receptor modulators - adverse effects (2) 2
fluorouracil - administration & dosage (2) 2
functional assessment (2) 2
health aspects (2) 2
internal medicine (2) 2
leucovorin - administration & dosage (2) 2
lumpectomy (2) 2
lymphatic metastasis (2) 2
male (2) 2
mastectomy, segmental (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10021, pp. 849 - 856
Summary Background Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated... 
Internal Medicine | INTRADUCTAL BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | RADIATION-THERAPY | B-17 | Breast Neoplasms - surgery | Triazoles - administration & dosage | Triazoles - adverse effects | Thrombosis - chemically induced | Age Factors | Humans | Middle Aged | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Carcinoma, Ductal, Breast - drug therapy | Mastectomy, Segmental | Antineoplastic Agents, Hormonal - therapeutic use | Postmenopause | Female | Embolism - chemically induced | Aromatase Inhibitors - therapeutic use | Triazoles - therapeutic use | Aromatase Inhibitors - administration & dosage | Carcinoma, Ductal, Breast - surgery | Double-Blind Method | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Combined Modality Therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - radiotherapy | Carcinoma, Ductal, Breast - radiotherapy | Tamoxifen - therapeutic use | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Lumpectomy | Medical colleges | Carcinoma | Radiation | Clinical trials | Postmenopausal women | Hormones | Tamoxifen | Radiotherapy | Biometry | Health maintenance organizations | Product development | Cancer | Chemotherapy | Womens health | Older people | Breast cancer | Radiation therapy | Cancer surgery
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2005, Volume 97, Issue 22, pp. 1652 - 1662
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10021, pp. 857 - 865
Journal Article
JAMA, ISSN 0098-7484, 06/2006, Volume 295, Issue 23, pp. 2727 - 2741
Journal Article
Cancer Epidemiology Biomarkers & Prevention, ISSN 1055-9965, 02/2017, Volume 26, Issue 2 Supplement, pp. A76 - A76
Journal Article
Cancer Prevention Research, ISSN 1940-6207, 06/2010, Volume 3, Issue 6, pp. 696 - 706
The selective estrogen-receptor modulator (SERM) tamoxifen became the first U. S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer... 
WOMEN | RISK-FACTORS | ONCOLOGY | ESTROGEN | FOLLOW-UP | OUTCOMES | MUTATIONS | NSABP | Uterus - pathology | Raloxifene Hydrochloride - adverse effects | Raloxifene Hydrochloride - pharmacology | Adenocarcinoma - pathology | Raloxifene Hydrochloride - therapeutic use | Cataract - chemically induced | Follow-Up Studies | Thromboembolism - chemically induced | Fractures, Spontaneous - epidemiology | Estrogens | Humans | Middle Aged | Osteoporosis, Postmenopausal - complications | Endometrial Neoplasms - chemically induced | Selective Estrogen Receptor Modulators - adverse effects | Risk | Cataract - epidemiology | Thromboembolism - epidemiology | Drug Utilization | Incidence | Selective Estrogen Receptor Modulators - therapeutic use | Aged, 80 and over | Adult | Female | Osteoporosis, Postmenopausal - prevention & control | Breast Neoplasms - epidemiology | Myocardial Ischemia - epidemiology | Neoplasms, Hormone-Dependent - prevention & control | Double-Blind Method | Neoplasm Invasiveness | Myocardial Ischemia - prevention & control | Fractures, Spontaneous - etiology | Endometrial Neoplasms - epidemiology | Neoplasms, Hormone-Dependent - epidemiology | Breast Neoplasms - prevention & control | Adenocarcinoma - prevention & control | Fractures, Spontaneous - prevention & control | Breast Neoplasms - pathology | Neoplasms, Hormone-Dependent - pathology | Tamoxifen - therapeutic use | Tamoxifen - pharmacology | Aged | Tamoxifen - adverse effects | Adenocarcinoma - epidemiology | Selective Estrogen Receptor Modulators - pharmacology | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 10066 - 10066
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2017, Volume 35, Issue 35, pp. 3942 - 3948
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 1/2009, Volume 113, Issue 2, pp. 315 - 320
Journal Article